Zofran
Indolent Non-hodgkin Lymphoma
Fox Chase Cancer CenterPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 81/ 100
Competitive context
5 Active assets in the Indolent Non-hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Obinutuzumab Reid Merryman, MD | Phase 2 | B |
Bendamustine Fox Chase Cancer Center | Phase 3 | B |
ibi376 Chinese PLA General Hospital | Phase 2 | B |
Glofitamab Reid Merryman, MD | Phase 2 | CCC |
Gdc-0449 The Lymphoma Academic Research Organisation | Phase 2 | CCC |
Car.K.28 UNC Lineberger Comprehensive Cancer Center | Phase 1 | CC |
Same molecule, other indications
Zofran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →